Check-Cap Stock (NASDAQ:CHEK)

Ownership Financials Chart

Previous Close

$1.06

52W Range

$0.56 - $3.45

50D Avg

$1.02

200D Avg

$1.66

Market Cap

$5.79M

Avg Vol (3M)

$1.32M

Beta

0.18

Div Yield

CHEK Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Mar 04, 2015

Website

CHEK Performance

CHEK Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-17.86M	$-20.03M	$-17.32M
Net Income	$-17.57M	$-19.25M	$-17.09M
EBITDA	$-17.65M	$-19.63M	$-17.12M
Basic EPS	$-3.00	$-3.39	$-4.13
Diluted EPS	$-3.00	$-3.39	$-4.13

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
STIM	Neuronetics, Inc.
BNR	Burning Rock Biotech Limited
PRE	Prenetics Global Limited
ACRS	Aclaris Therapeutics, Inc.
DRIO	DarioHealth Corp.
CSTL	Castle Biosciences, Inc.
BDSX	Biodesix, Inc.
NOTV	Inotiv, Inc.
SERA	Sera Prognostics, Inc.
FONR	FONAR Corporation
MDXH	MDxHealth SA